Shuang-Yang Li

Dr. Shuang-Yang Li

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2025 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
DLDongyi hong Liao
Dongyi hong Liao
YZYujie Zhang
Yujie Zhang
SLShuang-Yang Li
Shuang-Yang Li
HTHongmei Tang
Hongmei Tang
XBXue Bai
Xue Bai

1 January 2025 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Open access
LHLinrong He
Linrong He
RLRuolan Lei
Ruolan Lei
SLShuang-Yang Li
Shuang-Yang Li
XZXiaoying Zhao
Xiaoying Zhao
XHXinying He
Xinying He
YJYu Jiang
Yu Jiang
Hirudin has shown potential in promoting angiogenesis and providing neuroprotection in ischemic stroke; however, its therapeutic role in promoting cerebrovascular angiogenesis remains unclear. In this study, we aimed to investigate whether hirudin exerts neuroprotective effects by promoting angiogenesis through the regulation of the Wnt/β-catenin signaling pathway. An in vitro model of glucose and oxygen deprivation/reperfusion (OGD/R) was established using rat brain microvascular endothelial cells (BMECs). The effects of hirudin on OGD/R cell viability were assessed using the cell counting kit-8 (CCK-8) assay. The angiogenic potential of hirudin was evaluated using Transwell and tube formation assays. In vivo, a middle cerebral artery occlusion/reperfusion (MCAO/R) model was created in rats. The neuroprotective effects of hirudin were assessed using the modified neurological severity score (mNSS), Hematoxylin and eosin (H&E) staining, 2,3,5-Triphenyltetrazolium chloride (TTC) staining, and immunofluorescence staining. Dickkopf-1 (DKK1), a specific inhibitor of this pathway, was introduced in order to investigate the role of the Wnt/β-catenin pathway. The effects of hirudin on the Wnt/β-catenin pathway were examined through immunohistochemistry, western blotting, and reverse transcription quantitative polymerase chain reaction (RT-qPCR). Hirudin significantly improved BMEC survival and enhanced both cell migration and tube formation in the OGD/R model. In the MCAO/R model, hirudin reduced the mNSS score, alleviated pathological damage, decreased infarction volume, and increased the expression of key angiogenic factors, including CD34, vascular endothelial growth factor (VEGF), and angiopoietin-2 (Ang-2). In addition, hirudin activated the Wnt/β-catenin pathway, leading to elevated levels of Wnt3a and β-catenin. Hirudin has substantial neuroprotective effects associated with the promotion of angiogenesis in the ischemic penumbra. This mechanism is mediated by the regulation of the Wnt/β-catenin pathway.

30 September 2022 in Medicine
Verified
Journal Article
Open access
RWRaoqiong PhD Candidate Wang
Raoqiong PhD Candidate Wang
SLShuang-Yang Li
Shuang-Yang Li
LHLinyao Hao
Linyao Hao
ZWZhichuan Bs Wang
Zhichuan Bs Wang
ZGZhengxin Bs Ge
Zhengxin Bs Ge
SYSijin Yang
Sijin Yang
Background: The purpose of this study was to perform a pooled analysis of randomized controlled trials (RCT) of intravenous thrombolysis (IVT) versus bridging therapy of intravenous thrombolysis and mechanical thrombectomy (IVMT), comparing the efficacy and safety of the two in patients with acute ischemic stroke (AIS). Methods: All eligible RCT articles from database establishment to December 8, 2021 were searched in databases such as PubMed, Ovid, Embase, Web of science, Cochrane Library, etc. Efficacy outcomes were assessed by modified RANKIN scal (mRS) score, complete recanalization or reperfusion (TICI), National Institute of Health Stroke Scal (NIHSS) score, 90-day mortality, 24 to 36 h incidence of symptomatic intracranial hemorrhage (sICH). Results: Our study included 6 RCT involving 1717 patients. The proportion of the primary efficacy outcome (mRS score 0‐2 at 90 days) was significantly different between IVT and IVMT (OR 0.51; 95% CI 0.35‐0.76). For the secondary efficacy outcome, the study found a significant difference in the proportion of TICI (pooled OR was 0.055, 95% CI 0.07‐0.33). There was a significant difference in the 24 h NIHSS score between the IVT group and the IVMT group (pooled MD was 3.25, 95% CI 0.80‐5.70). There were no significant differences in the NIHSS score at 90 days, the death rate at 90 days, and the sICH at 24 to 36 hours between the two groups. Conclusions: This study confirms that IVMT is more effective and safe than IVT alone in patients with AIS. However, more and higher-quality randomized clinical trials comparing IVMT to IV alone are warranted for validation.

5 August 2025 in Frontiers in Physiology
Verified
Journal Article
Open access
PDF file
HZHuang Zhipeng
Huang Zhipeng
LSLiu Shan
Liu Shan
ZDZhang Dechou
Zhang Dechou
SLShuang-Yang Li
Shuang-Yang Li
XBXue Bai
Xue Bai
Intracerebral haemorrhage (ICH), while only constituting 10% to 15% of strokes, is associated with significantly elevated disability and mortality rates, with survivors often experiencing profound and enduring neurological impairment. It is essential to elucidate the pathogenic mechanisms of subsequent injury following ICH and preserve the function of the remaining brain tissue. Oxidative stress is a key mechanism of neurological damage after intracerebral hemorrhage. This letter focuses on the pathophysiological basis and potential antioxidant strategies to ameliorate hypoperfusion injury following ICH, hoping to illustrate novel perspectives on the therapy of this condition.Hemorrhage and ischaemia appear to be contradictory, but just as hemorrhagic transformation can occur in cerebral infarction, hypoperfusion has a negative impact on the responsiveness and self-regulation of cerebral vessels, which is directly related to the poor prognosis of patients with cerebral haemorrhage 1 . Perihematomal tissues in ICH have persistent hypoperfusion within one week of onset and even in the chronic stage, which can be observed in neuroimaging as decreased diffusion-perfusion, decreased regional cerebral blood flow (rCBF) and regional cerebral blood volume (rCBV), and delayed mean transit time (MTT) and time-to-peak (TTP) adjacent to hematoma 2,3 . The self-regulation of cerebral blood flow (CBF) ensures that blood flow to the brain remains stable even when systemic blood pressure changes, preventing ischemic damage when hemodynamics are unstable. However, the hematoma and its consequent cerebral edema can alter oxygen and nutrition flow to afflicted brain regions, complicating prediction models due to the intricate connections between risk factors and clinical consequences.CBF is regulated by vascular baroreflex, renin-angiotensin system and endothelial nitric oxide release. Small intracranial vessels change vascular resistance through contraction and relaxation. Through changes in physiological needs and compensatory pathological changes, CBF balance is dynamically maintained to maintain oxygen and energy supply in the brain 4 . After cerebral vessel rupture, on the one hand, the hematoma formed has a significant space-occupying effect, and could directly compress surrounding brain tissue. The mechanical space-occupying compression of hematoma causes a rapid increase in intracranial pressure, which is first augmented by reflex hypertension and CBF pressure. However, the hematoma and perihematoma edema directly mechanically compress the vessels of the surrounding tissues, obstruct venous return and cause a decrease in the volume of the surrounding vascular bed. These alternations lead to the reflex dysfunction of the vessels and increased intracranial pressure compresses the lesions around the hematoma, resulting in microcirculation disorders. And the toxic reaction caused by hematoma components and their decomposition metabolites can result in secondary damage, such as neuroinflammation, brain edema and worsening high intracranial pressure, and interfere with neurovascular coupling, tissue hypoxia and potentially irreversible biochemical damage.In the formation and progression of ICH hypoperfusion, the space-occupying effect of the hematoma and its secondary effects can directly or indirectly damage various cellular components in the central nervous system, including inducing endothelial cell dysfunction, neurotoxicity leading to neuronal apoptosis, and abnormal polarization of microglia aggravating neuroinflammation. Cerebral endothelial cell (CEC) is the core of blood perfusion and the basis of blood-brain barrier(BBB. It helps to maintain cerebral homeostasis. CEC can respond quickly and compensatorily regulate CBF in the early phases of cerebral perfusion alterations by sensing mechanical compression, blood flow shear stress, and other mechanisms. Hypoperfusion causes a decrease in oxygen and glucose supply, blocks the synthesis of adenosine triphosphate (ATP), and impairs endothelial mitochondrial function. And the failure of the cell membrane ion pumps cause cerebral microvascular endothelial dysfunction, inducing neurovascular uncoupling and diminished oxygenation capacity. Meanwhile, as the main component of the BBB, pathological reactions, including neuroinflammation and oxidative stress, can damage the selective transport function and tight junctions of CECs, allowing neurotoxic substances such as peripheral cytokines to enter the central nervous system, further aggravating neurological damage. Additionally, the above pathological and physiological links do not appear alone or step by step, but interact with each other to form a vicious circle. Therefore, focusing on improving the CEC function is of great value in improving perihematomal hypoperfusion injury.The secondary damage of ICH is the primary connection to the subsequent impact of neurological impairment. Endothelial dysfunction following ICH results in inadequate bioavailability of nitric oxide (NO), which is deactivated by its interaction with superoxide anions, producing superoxynitrite. The disproportion between the production and elimination of reactive oxygen free radicals leads to oxidative stress. An abundance of free radicals exacerbates CEC dysfunction by impairing DNA, disrupting signal transduction, inducing cell apoptosis and autophagy, and influencing gene expression regulation. This culminates in CBF imbalance and BBB damage, while also facilitating the activation of immune cells within the central nervous system, thereby creating an inflammatory milieu that further deteriorates endothelial function and exacerbates BBB compromise and abnormal brain perfusion. Recent investigations also indicate that endothelin-1, soluble nicotinamide adenine dinucleotide 2-derived peptide (sNOX2-dp), and asymmetric dimethylarginine may contribute to the development of hypoperfused tissue surrounding the hematoma 5...

1 August 2025
Verified
Journal Article
Closed access
WRWang Raoqiong
Wang Raoqiong
HLHao Linyao
Hao Linyao
LYL U Ye
L U Ye
WLWang Lingxue
Wang Lingxue
LJL I Jianrong
L I Jianrong
XBXue Bai
Xue Bai

29 June 2026 in Frontiers in Pharmacology
Verified
Journal Article
Open access
LHLin-Yao Hao
Lin-Yao Hao
ZHZhi-Peng Huang
Zhi-Peng Huang
HZHui-Min Zhang
Hui-Min Zhang
YPYu-Ting Pu
Yu-Ting Pu
LWLing-Xue Wang
Ling-Xue Wang
SLShuang-Yang Li
Shuang-Yang Li
Background and purpose: Cerebral ischemia-reperfusion injury disrupts the brain-gut axis, which involves the activation of the toll-like receptor 4 (TLR4)/myeloid differentiation factor 88 (MyD88)/nuclear factor-kappa B (NF-κB) pathway and gut microbiota dysregulation. Acorus tatarinowii Schott (AT) and Panax notoginseng saponins are traditional Chinese medicines with neuroprotective potential, yet the mechanism underlying their combined action remains elusive. Materials and methods: 144 Sprague-Dawley rats were divided into groups including: sham, model (transient middle cerebral artery occlusion/reperfusion, MCAO/R), and drug-treated groups receiving A. tatarinowii Schott (AT), P. notoginseng saponins (PNS), or their combination (PAT). To evaluate efficacy under heightened inflammatory conditions, parallel groups were pre-treated with lipopolysaccharide (LPS, a TLR4 pathway agonist) before MCAO/R and subsequent drug administration (e.g., LPS + MCAO/R, LPS + AT, LPS + PNS, LPS + PAT, etc.). Neurological deficits (Longa score), cerebral infarct volume (TTC staining), intestinal motility, and histopathology (Hematoxylin-eosin staining, transmission electron microscopy) were analyzed. Additionally, levels of tight junction proteins (ZO-1, claudin-5, occludin), TLR4 pathway components, and inflammatory cytokines (TNF-α, IL-6) were assessed using Western blot and/or immunohistochemistry. Gut microbiota composition was evaluated via 16S rDNA sequencing. Results: Compared with either monotherapy, the combined AT–PNS treatment produced greater improvements in neurological function, reduced cerebral infarct volume, preserved blood-brain and intestinal barrier integrity, and attenuated TLR4/MyD88/NF-κB pathway activation. The combination was also associated with partial normalization of cecal microbiota composition, including an increased Firmicutes/Bacteroidota ratio and reduced Proteobacteria abundance. These effects were attenuated but remained detectable under LPS-induced inflammatory challenge. Conclusion: Combined AT–PNS treatment ameliorated brain-gut axis dysfunction after cerebral ischemia-reperfusion injury and showed greater efficacy than either monotherapy in this fixed-dose experimental design. These effects were accompanied by suppression of TLR4/MyD88/NF-κB signaling, improved barrier integrity, and associated changes in gut microbiota composition. Because the present study did not include dose-response matrices, a formal dose-response interaction profile and a causal microbiota-TLR4 mechanism remain to be established in future studies.